/

OCGN

Ocugen, Inc.Closed

0.8854−0.06 −6.52%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.9006 +1.72%

Open

0.9454

Prev close

0.9472

Day range

0.87000.9454

52-week range

0.87002.73

Volume

6.86M1.13×

Mkt cap

300.25M

P/E ttm

—

Fwd P/E

-3.50

EPS ttm

-0.2600

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−67.51%

Price Chart

Yahoo Finance · delayed

OCGNOct 13, 2026O 0.9450H 0.9450L 0.8700C 0.8850−0.0620 (−6.55%)Vol 6.87M

SMA 501.1820
SMA 2001.4784

1Y change −44.69% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

OCGN Ocugen, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −14.90%
1 month: −13.24%
3 months: −38.11%
6 months: −50.83%
Year to date: −34.44%
1 year: −44.69%

Valuation & ownership

Market cap: 300.25M
Enterprise value: 288.18M
P/E (ttm): —
Forward P/E: -3.50
PEG ratio: —
Price / book: —
Price / sales (ttm): 65.54
EV / EBITDA: -4.29
EPS (ttm): -0.2600
EPS (forward): -0.2533
Beta (5y monthly): 2.27
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 339.11M
Float: 333.78M
Short % of float: 30.09%
Short ratio (days): 11.75
Held by insiders: 1.54%
Held by institutions: 43.41%
Avg volume (3m): 6.05M
50-day average: 1.19
200-day average: 1.48
52-week change: −44.69%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 29.3
vs 50-day SMA: −25.13%
vs 200-day SMA: −40.14%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.66%
Realised vol (20d, ann.): 50.7%
From 52-week high: −67.52%
From 52-week low: +1.72%

ANR

Analyst Consensus

6 analysts

Consensus

Strong buy

1.17 on a 1 (strong buy) – 5 (sell) scale

Mean target

12.17

+1,274.14% implied

Low 8.00Median 10.50High 22.00

Recommendation trend

Now6 / 0 / 0
1m ago6 / 0 / 0

DES

About Ocugen, Inc.

Yahoo Finance profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 116
Headquarters: Malvern, PA, United States
Website: ocugen.com
Officers

SEAS

Seasonality · OCGN

2014–2026 · monthly returns

Strongest month Feb +46.89%Weakest month Nov −19.88%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	7.4	25.5	-0.5	-4.4	-20.2	10.9	-19.6	8.1	-22.6	-14.0			−34.4%
2025	-9.7	-10.3	8.3	5.8	11.9	16.0	6.2	-1.0	59.8	-4.3	-20.5	8.9	+67.7%
2024	-6.8	74.6	75.2	-19.5	31.1	-10.4	-9.4	-7.5	-23.7	-8.2	7.8	-18.0	+40.0%
2023	-2.3	-21.6	-14.4	-16.3	-35.6	18.0	13.3	-29.9	-7.2	-8.0	5.2	48.6	−55.8%
2022	-22.0	-0.8	-6.3	-33.6	8.2	-4.2	13.7	0.0	-31.0	-3.4	-9.3	-16.7	−71.4%
2021	-3.3	518.6	-38.0	86.6	-31.1	-8.0	-16.4	13.1	-5.4	64.9	-46.5	-28.2	+148.6%
2020	1.9	-15.1	-37.6	11.4	-1.0	-29.0	134.1	-32.4	-10.9	-9.4	13.5	473.7	+251.9%
2019	136.4	-40.4	-6.5	62.9	1.6	-0.5	-5.8	33.3	-80.2	-43.2	-76.6	37.2	−90.2%
2018	35.1	-6.9	6.6	-3.6	-12.8	8.2	-11.6	32.1	-81.3	25.7	-37.5	-79.4	−95.7%
2017	-4.8	5.0	3.6	0.6	-7.5	11.2	3.4	-0.5	7.6	7.6	-6.6	3.0	+22.8%
2016	-14.0	-13.6	-11.9	-0.9	-18.1	-8.1	12.2	62.1	3.2	-16.2	-28.3	-13.5	−52.3%
2015	-23.1	26.2	-6.4	-18.3	2.3	-22.6	-1.3	-2.9	-35.6	3.2	-20.0	6.4	−68.2%
2014													—

INSD

Insider Activity · OCGN

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

21K shares

Sells, 6 months

526K shares

Net shares

−505K

Net change in insider shares

−8.80%

Date	Insider	Transaction	Shares	Value
Sep 8, 2026	Musunuri Shankar Ph.DChief Executive Officer	Sale at price 1.12 per share.	526K	$589.11K
Jun 14, 2026	Johnson-Greene Treerita EssalimaChief Financial Officer	Purchase at price 1.23 per share.	21K	$25.83K
Mar 31, 2026	Zhang JungeDirector	Conversion of Exercise of derivative security at price 0.46 - 1.42 per share.	194.1K	$154.30K
Jan 1, 2026	Musunuri Shankar Ph.DChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	3.12M	—
Jan 1, 2026	Ramachandran RameshOfficer	Stock Award(Grant) at price 0.00 per share.	207.3K	—
Nov 25, 2024	Fernandes PrabhavathiDirector	Purchase at price 0.91 per share.	10K	$9.10K
Nov 21, 2024	Castillo Kirsten MDirector	Purchase at price 0.91 per share.	25K	$22.85K

OCGN

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

OCGN

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ocugen, Inc.

Seasonality · OCGN

Insider Activity · OCGN

Congress Trades · OCGN

Investors Holding OCGN

Investors Holding OCGN

Congress Trades · OCGN

Insider Activity · OCGN

Seasonality · OCGN

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ocugen, Inc.

Financial Snapshot

Earnings & Dividends

News